Genetics and molecular epidemiology of metabolic syndrome-related traits: Focus on metabolic profiling of lipid-lowering therapies and fatty liver, and the role of genetic factors in inflammatory load
Thesis event information
Date and time of the thesis defence
Place of the thesis defence
Auditorium P117 (Aapistie 5B)
Topic of the dissertation
Genetics and molecular epidemiology of metabolic syndrome-related traits: Focus on metabolic profiling of lipid-lowering therapies and fatty liver, and the role of genetic factors in inflammatory load
Doctoral candidate
Master of science Eeva Sliz
Faculty and unit
University of Oulu Graduate School, Faculty of Medicine, Center for Life Course Health Research
Subject of study
Public health science
Opponent
Professor Bertrand Cariou, University of Nantes
Custos
Professor Johannes Kettunen, University of Oulu
Novel insights into molecular mechanisms of metabolic syndrome
The present thesis focuses on the detailed molecular mechanisms of metabolic syndrome-related traits. The results indicate that PCSK9 inhibition is slightly less efficacious at lowering VLDL cholesterol than statins. The diversity in the molecular mechanisms of non-alcoholic fatty liver disease is highlighted by the observed discrepancies in the metabolic effects of its risk genotypes. The genetic associations with circulating markers of inflammation provide novel information on genetic mechanisms contributing to the inflammatory load.
The metabolic consequences of lipid-lowering medications and fatty liver were studied using genotype data and comprehensive blood analyses. Genome-wide tests were performed to identify genetic factors associating with inflammatory markers.
Metabolic syndrome is characterized by disturbances in multiple organ systems including cardiovascular, digestive, and immune systems. Dyslipidemia, fatty liver, and low-grade inflammation are features closely associated with the presence of metabolic syndrome. These metabolic risk factors predispose to cardiovascular disease, type 2 diabetes, and increased mortality.
Due to high prevalence and severe co-morbidities, metabolic syndrome constitutes a major burden for public health. Improved understanding of the detailed molecular mechanisms could provide novel strategies for the treatment and preferably prevention of the metabolic syndrome-related health issues.
The metabolic consequences of lipid-lowering medications and fatty liver were studied using genotype data and comprehensive blood analyses. Genome-wide tests were performed to identify genetic factors associating with inflammatory markers.
Metabolic syndrome is characterized by disturbances in multiple organ systems including cardiovascular, digestive, and immune systems. Dyslipidemia, fatty liver, and low-grade inflammation are features closely associated with the presence of metabolic syndrome. These metabolic risk factors predispose to cardiovascular disease, type 2 diabetes, and increased mortality.
Due to high prevalence and severe co-morbidities, metabolic syndrome constitutes a major burden for public health. Improved understanding of the detailed molecular mechanisms could provide novel strategies for the treatment and preferably prevention of the metabolic syndrome-related health issues.
Last updated: 1.3.2023